Satsuma Pharmaceuticals Long Term Debt

Satsuma Pharmaceuticals (STSA) currently reports a long-term debt of $0 as of March 2023. That compares with $100K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Satsuma Pharmaceuticals's long-term debt history and peer comparisons.

Satsuma Pharmaceuticals's long-term debt decreased from $100K to $0 — a 100.0% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Satsuma Pharmaceuticals reported $0 in long-term debt as of March 2023. That compares with $100K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Satsuma Pharmaceuticals, and consider following STSA for alerts when major investors trade the stock.

Satsuma Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing STSA with unrelated industries.